Barclays PLC Has $1.15 Million Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Barclays PLC raised its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 357.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,837 shares of the medical instruments supplier’s stock after buying an additional 6,905 shares during the quarter. Barclays PLC owned 0.16% of Mesa Laboratories worth $1,148,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Meros Investment Management LP bought a new position in Mesa Laboratories during the second quarter valued at about $2,456,000. State Street Corp increased its position in shares of Mesa Laboratories by 9.2% during the third quarter. State Street Corp now owns 214,148 shares of the medical instruments supplier’s stock valued at $27,809,000 after purchasing an additional 18,128 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Mesa Laboratories by 38.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 62,609 shares of the medical instruments supplier’s stock valued at $8,130,000 after purchasing an additional 17,450 shares in the last quarter. Eagle Asset Management Inc. lifted its position in Mesa Laboratories by 10.9% in the third quarter. Eagle Asset Management Inc. now owns 165,955 shares of the medical instruments supplier’s stock worth $19,722,000 after purchasing an additional 16,293 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Mesa Laboratories by 7.1% in the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier’s stock worth $11,444,000 after purchasing an additional 8,722 shares during the period. 90.60% of the stock is owned by institutional investors.

Mesa Laboratories Stock Down 2.4 %

MLAB stock opened at $131.10 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. The stock has a market capitalization of $712.00 million, a P/E ratio of -2.88 and a beta of 0.82. The business has a 50-day moving average of $124.12 and a 200-day moving average of $120.65. Mesa Laboratories, Inc. has a fifty-two week low of $83.68 and a fifty-two week high of $147.34.

Mesa Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, February 28th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date is Friday, February 28th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.40%.

Analyst Ratings Changes

MLAB has been the subject of a number of recent research reports. Evercore ISI increased their target price on Mesa Laboratories from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com cut Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th.

Insider Buying and Selling at Mesa Laboratories

In other news, CEO Gary M. Owens sold 2,518 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total transaction of $286,095.16. Following the transaction, the chief executive officer now owns 45,888 shares in the company, valued at approximately $5,213,794.56. This trade represents a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.40% of the company’s stock.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.